<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties manuscript?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-journal-id">8710219</journal-id><journal-id journal-id-type="pubmed-jr-id">1493</journal-id><journal-id journal-id-type="nlm-ta">AIDS</journal-id><journal-id journal-id-type="iso-abbrev">AIDS</journal-id><journal-title-group><journal-title>AIDS (London, England)</journal-title></journal-title-group><issn pub-type="ppub">0269-9370</issn><issn pub-type="epub">1473-5571</issn></journal-meta><article-meta><article-id pub-id-type="pmid">31764095</article-id><article-id pub-id-type="pmc">11000142</article-id><article-id pub-id-type="doi">10.1097/QAD.0000000000002390</article-id><article-id pub-id-type="manuscript">HHSPA1975648</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>HIV-1 genetic diversity to estimate time of infection and infer adherence to preexposure prophylaxis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Council</surname><given-names>Olivia D.</given-names></name><xref rid="A1" ref-type="aff">a</xref><xref rid="FN1" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><name><surname>Ruone</surname><given-names>Susan</given-names></name><xref rid="A1" ref-type="aff">a</xref><xref rid="FN1" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><name><surname>Mock</surname><given-names>Philip A.</given-names></name><xref rid="A2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Khalil</surname><given-names>George</given-names></name><xref rid="A3" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>Martin</surname><given-names>Amy</given-names></name><xref rid="A1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Curlin</surname><given-names>Marcel E.</given-names></name><xref rid="A4" ref-type="aff">d</xref></contrib><contrib contrib-type="author"><name><surname>McNicholl</surname><given-names>Janet M.</given-names></name><xref rid="A1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Heneine</surname><given-names>Walid</given-names></name><xref rid="A1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Leelawiwat</surname><given-names>Wanna</given-names></name><xref rid="A2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Choopanya</surname><given-names>Kachit</given-names></name><xref rid="A5" ref-type="aff">e</xref></contrib><contrib contrib-type="author"><name><surname>Vanichseni</surname><given-names>Suphak</given-names></name><xref rid="A5" ref-type="aff">e</xref></contrib><contrib contrib-type="author"><name><surname>Cherdtrakulkiat</surname><given-names>Thitima</given-names></name><xref rid="A2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Anekvorapong</surname><given-names>Rapeepan</given-names></name><xref rid="A5" ref-type="aff">e</xref></contrib><contrib contrib-type="author"><name><surname>Martin</surname><given-names>Michael</given-names></name><xref rid="A2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Garc&#x000ed;a-Lerma</surname><given-names>Jos&#x000e9; Gerardo</given-names></name><xref rid="A1" ref-type="aff">a</xref></contrib></contrib-group><aff id="A1"><label>a</label>Laboratory Branch, Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, US Centers for Disease Control and Prevention, Atlanta, Georgia, USA</aff><aff id="A2"><label>b</label>Thailand Ministry of Public Health &#x02013; U.S. Centers for Disease Control and Prevention Collaboration, Nonthaburi, Thailand</aff><aff id="A3"><label>c</label>Quantitative Sciences and Data Management Branch, Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia</aff><aff id="A4"><label>d</label>Department of Medicine, Division of Infectious Diseases, Oregon Health and Sciences University, Portland, Oregon, USA</aff><aff id="A5"><label>e</label>Bangkok Tenofovir Study Group, Bangkok, Thailand.</aff><author-notes><fn fn-type="equal" id="FN1"><label>*</label><p id="P1">Olivia D. Council and Susan Ruone contributed equally to this work.</p></fn><fn fn-type="con" id="FN2"><p id="P2">Author contributions: O.D.C., S.R. and J.G.G.-L. conceived and designed the experiments. O.C., S.R., P.M., A.M., M.E.C., J.M., W.H., W.L., K.C., S.V., T.C., R.A. and M.M acquired data and/or performed the experiments. O.C., S.R., G.K., M.M. and J.G.G.-L. analyzed the data. J.G.G.-L. wrote the article.</p></fn><corresp id="CR1">Correspondence to Jos&#x000e9; Gerardo Garc&#x000ed;a-Lerma, Laboratory Branch, Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, US Centers for Disease Control and Prevention, MS H18-2, 1600 Clifton Road, Atlanta, GA 30329, USA. <email>jng5@cdc.gov</email></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>1</day><month>4</month><year>2024</year></pub-date><pub-date pub-type="ppub"><day>01</day><month>12</month><year>2019</year></pub-date><pub-date pub-type="pmc-release"><day>08</day><month>4</month><year>2024</year></pub-date><volume>33</volume><issue>15</issue><fpage>2299</fpage><lpage>2307</lpage><abstract id="ABS1"><sec id="S1"><title>Objective:</title><p id="P3">To estimate time of HIV infection in participants from the Bangkok Tenofovir Study (BTS) with daily oral tenofovir disoproxil fumarate (TDF) for preexposure prophylaxis (PrEP) and relate infection with adherence patterns.</p></sec><sec id="S2"><title>Design:</title><p id="P4">We used the diversity structure of the virus population at the first HIV RNA-positive sample to estimate the date of infection, and mapped these estimates to medication diaries obtained under daily directly observed therapy (DOT).</p></sec><sec id="S3"><title>Methods:</title><p id="P5">HIV genetic diversity was investigated in all 17 PrEP breakthrough infections and in 16 placebo recipients. We generated 10&#x02013;25 HIV <italic toggle="yes">env</italic> sequences from each participant by single genome amplification, and calculated time since infection (and 95% confidence interval) using Poisson models of early virus evolution. Study medication diaries obtained under daily DOT were then used to compute the number of missed TDF doses at the approximate date of infection.</p></sec><sec id="S4"><title>Results:</title><p id="P6">Fifteen of the 17 PrEP breakthrough infections were successfully amplified. Of these, 13 were initiated by a single genetic variant and generated reliable estimates of time since infection (median = 47 [IQR = 35] days). Eleven of these 13 were under daily DOT at the estimated time of infection. Analysis of medication diaries in these 11 participants showed 100% adherence in five, 90&#x02013;95% adherence in two, 55% adherence in one, and nonadherence in three.</p></sec><sec id="S5"><title>Conclusion:</title><p id="P7">We estimated time of infection in participants from BTS and found several infections when high levels of adherence to TDF were reported. Our results suggest that the biological efficacy of daily TDF against parenteral HIV exposure is not 100%.</p></sec></abstract><kwd-group><kwd>adherence</kwd><kwd>HIV-1 diversity</kwd><kwd>preexposure prophylaxis</kwd><kwd>prevention</kwd><kwd>tenofovir</kwd></kwd-group></article-meta></front><body><sec id="S6"><title>Introduction</title><p id="P8">With approximately 37.9 million people living with HIV-1 at the end of 2018 and 1.7 million people newly infected in 2018, the HIV-1 epidemic continues to be a major public health problem [<xref rid="R1" ref-type="bibr">1</xref>]. Daily preexposure prophylaxis (PrEP) with the combination of oral emtricitabine (FTC) and TDF is highly effective in preventing HIV-1 infection [<xref rid="R2" ref-type="bibr">2</xref>]. However, for PrEP to be effective, high medication adherence is required. Antiretroviral drug detection in plasma or peripheral blood mononuclear cells (PBMCs) is considered the best indicator of adherence, and in major PrEP trials was a good predictor of PrEP effectiveness [<xref rid="R3" ref-type="bibr">3</xref>&#x02013;<xref rid="R8" ref-type="bibr">8</xref>].</p><p id="P9">Although assessing adherence by measuring drug concentrations in plasma or PBMCs has become essential for understanding PrEP effectiveness, this approach has limitations. Levels of tenofovir or FTC in plasma provide information about recently ingested doses, but not about consistency of drug dosing over time. Concentrations of tenofovir diphosphate (TFV-DP) in PBMCs or dried blood spots provide information about pill-taking behavior and mean number of doses taken per week during the preceding 1&#x02013;2 or 4&#x02013;6 weeks, respectively [<xref rid="R9" ref-type="bibr">9</xref>&#x02013;<xref rid="R11" ref-type="bibr">11</xref>]. However, these measurements provide average TFV-DP levels and cannot capture cycles of low adherence that may associate with increased HIV risk. A recent modeling study showed that PrEP adherence patterns had a substantial impact on protection even when the same number of pills was taken [<xref rid="R12" ref-type="bibr">12</xref>]. Optimally, measures of adherence should rely on pill-taking behavior and drug levels at the precise time of HIV-1 infection. This analysis can be done in trials where PrEP is administered under daily directly observed therapy (DOT) and HIV-1 testing is done frequently enough to identify persons in early stages of HIV acquisition (Fiebig stages I or II of infection).</p><p id="P10">In this study, we sought to characterize pill-taking behavior at the approximate date of HIV infection in participants from the Bangkok Tenofovir Study (BTS) study with daily oral TDF for PrEP among persons who inject drug (PWID) [<xref rid="R6" ref-type="bibr">6</xref>]. We first created adherence maps using medication diaries of participants who came to the clinics daily to receive study drug (daily DOT) in the 3 months prior to seroconversion. We then calculated the approximate date of HIV infection (and 95% confidence interval) for each of these participants using Poisson models of early virus evolution. The Poisson-Fitter and Shifted Poisson Mixture models use the nucleotide diversity of the HIV-1 population to provide estimates of time since infection with 95% confidence intervals [<xref rid="R13" ref-type="bibr">13</xref>,<xref rid="R14" ref-type="bibr">14</xref>]. The underlying assumption is that during the early weeks of HIV-1 infection and prior to the onset of host immune responses, the virus population grows exponentially with a random accumulation of mutations [<xref rid="R15" ref-type="bibr">15</xref>]. The models are not influenced by viremia levels, assume a virus generation time of 2 days, a mutation rate of 2.16 &#x000d7; 10<sup>&#x02212;5</sup> mutations per base pair per cycle, and a basic reproductive ratio of 6 [<xref rid="R16" ref-type="bibr">16</xref>&#x02013;<xref rid="R18" ref-type="bibr">18</xref>]. These mathematical tools have been extensively validated using HIV <italic toggle="yes">env</italic> sequences from individuals at Fiebig stages I&#x02013;V of infection, and provide estimates of time since infection that generally fall within the range of Fiebig-based estimates [<xref rid="R13" ref-type="bibr">13</xref>,<xref rid="R14" ref-type="bibr">14</xref>,<xref rid="R19" ref-type="bibr">19</xref>,<xref rid="R20" ref-type="bibr">20</xref>].</p><p id="P11">We mapped the approximate date of infection in PrEP breakthrough infections from BTS with medication diaries generated under DOT, and document infections when high levels of adherence to TDF were reported.</p></sec><sec id="S7"><title>Methods</title><sec id="S8"><title>Study samples</title><p id="P12">The BTS trial was a randomized, double-blind, placebo-controlled trial that evaluated the safety and efficacy of daily TDF in reducing HIV-1 transmission among PWID. In this trial, 2413 participants were randomly assigned to daily TDF or placebo and could choose daily DOT (including weekends) or monthly visits without DOT. Participants were on DOT an average of 86.9% of the time with a median adherence on DOT of 94.8% [<xref rid="R6" ref-type="bibr">6</xref>].</p><p id="P13">We attempted to characterize HIV-1 genetic diversity in all 17 incident infections in the TDF group, and in 16 of the 33 incident infections from the placebo group. Of the 17 participants in the TDF group, amplification was not successful in two (TDF16 and TDF17, <xref rid="T1" ref-type="table">Table 1</xref>). Genetic diversity was investigated in plasma collected at the first HIV-1 RNA-positive visit. This visit coincided with the seroconversion visit (Genetic Systems HIV-1/HIV-2 plus O enzyme-immunoassay) in 12 of the 15 infections in the TDF group, and in 15 of the 16 infections in the placebo group [<xref rid="R6" ref-type="bibr">6</xref>,<xref rid="R21" ref-type="bibr">21</xref>]. The concentrations of TFV in plasma collected at this visit were measured as previously described using validated high-performance liquid chromatography&#x02013;tandem mass spectrometry methods with a lower limit of detection of 5 ng/ml [<xref rid="R22" ref-type="bibr">22</xref>].</p></sec><sec id="S9"><title>Single genome amplification of HIV-1 <italic toggle="yes">env</italic> and sequence analysis</title><p id="P14">Single genome amplification was performed following a standard protocol using primers specific for HIV-1 subtype B or AE [<xref rid="R23" ref-type="bibr">23</xref>,<xref rid="R24" ref-type="bibr">24</xref>]. Briefly, 30 &#x003bc;l of plasma HIV-1 RNA were added to a cocktail containing reverse primer envB3out (subtype B) or KenvR1 (subtype AE) and Superscript III reverse transcriptase (SSIII reverse transcriptase; Invitrogen). Reverse transcription was done at 50 &#x000b0;C for 60 min and 55 &#x000b0;C for 60 min. The cocktail was heated at 70 &#x000b0;C for 15 min to inactivate SSIII reverse transcriptase, and then treated with RNase H at 37 &#x000b0;C for 20 min to remove the RNA template. Serial dilutions of the reverse transcriptase-generated cDNA were made to identify dilutions of cDNA resulting in less than 30% of positive wells by PCR. On the basis of a Poisson distribution, amplifications at this dilution represent sequences derived from a single cDNA template [<xref rid="R25" ref-type="bibr">25</xref>].</p><p id="P15">The first round of PCR amplification was performed using 1&#x02013;2 &#x003bc;l of appropriately diluted cDNA and a cocktail containing Platinum <italic toggle="yes">Taq</italic> High-Fidelity (Invitro-gen, Carlsbad, California, USA) and primers envB5out/envB3out (subtype B) or K-R1 or NenvF1/K-R1 or NenvR1 (subtype AE) [<xref rid="R23" ref-type="bibr">23</xref>,<xref rid="R24" ref-type="bibr">24</xref>]. A 1 &#x003bc;l volume was then used for a nested PCR reaction using primer pair envB5in/envB3in (subtype B) or K-R2 or NenvF2/K-R2 or NenvR2 (subtype AE) [<xref rid="R23" ref-type="bibr">23</xref>,<xref rid="R24" ref-type="bibr">24</xref>]. PCR products were visualized on a 1% UltraPure Agarose gel (Invitrogen) using a BioRad SubCell GTgel apparatus and purified using the QIAquick PCR Purification Kit (Qiagen, German-town, MD USA). Sequences (~1 kb) representing the V1&#x02013;V5 and flanking regions of HIV-1 <italic toggle="yes">env</italic> were obtained from 10 to 25 amplicons per sample. Sequencing was done with the BigDye Terminator v1.1 Cycle Sequencing kit in an ABI3130xl automated sequencer. We attempted to generate at least 20 sequences per participant although this was not always possible because of low viremias and limited plasma availability. Sequences with evidence of mixed bases (median of 1 (0&#x02013;3) per participant) were excluded from the analysis.</p></sec><sec id="S10"><title>Calculation of time since infection and computation of missed tenofovir disoproxil fumarate doses</title><p id="P16">The degree of virus genetic diversity seen in plasma corresponding to the first HIV-1 RNA positive clinic visit was used to estimate time since infection using the Poisson-Fitter tool or the Shifted Poisson Mixture Model (SPMM). Poisson-Fitter calculates time since infection in homogeneous infections, that is, initiated by a single genetic strain [<xref rid="R13" ref-type="bibr">13</xref>]. The tool (available at <ext-link xlink:href="http://www.hiv.lanl.gov/content/sequence/POISSON_FITTER/poisson_fitter.html" ext-link-type="uri">http://www.hiv.lanl.gov/content/sequence/POISSON_FITTER/poisson_fitter.html</ext-link>) detects if the distribution of mutations in a set of HIV-1 sequences is indicative of a population evolving from a single variant through random accumulation of mutations. When the model is satisfied, Poisson-Fitter provides an estimate of time since infection with 95% confidence intervals. A small goodness-of-fit <italic toggle="yes">P</italic> value (&#x0003c;0.1) denotes divergence from a Poisson distribution and is indicative of heterogeneous infection or early onset of immune selection pressure [<xref rid="R13" ref-type="bibr">13</xref>]. We excluded hypermutated positions and hypermutated sequences found to be significantly enriched with a <italic toggle="yes">P</italic> value less than 0.1. This correction controls for APOBEC3G/F-mediated mutation enrichment that occurs at a higher rate than the background mutation rate.</p><p id="P17">A second model called the SPMM was used to calculate time since infection in multivariant infections. This model (available at <ext-link xlink:href="http://p512.usc.edu/" ext-link-type="uri">http://p512.usc.edu/</ext-link>) segregates distinct viral lineages and assumes no preferential selection of a particular lineage within the first few weeks of infection [<xref rid="R14" ref-type="bibr">14</xref>]. A <italic toggle="yes">P</italic> value less than 0.05 implies a significant deviation from the model. Prior to analysis, the alignments were checked for recombination using Simplot and the Recombination Detection Program (RDP v4.94).</p><p id="P18">We first tested all the specimens by the Poisson-Fitter tool, and retested those that did not fit the model by SPMM. Interval estimates of time since infection (i.e. 95% confidence intervals) generated with Poisson-Fitter or SPMM were then integrated with each participant study medication diaries to calculate the number of TDF pills missed within this period of time. We used Poisson point estimates to define the day of infection, and counted the number of TDF doses missed within the 95% confidence interval for this value (see <xref rid="F1" ref-type="fig">Fig. 1</xref> for a schematic representation). To minimize potential bias associated with self-reported adherence, we limited our analysis to the 11 participants that were under daily DOT during the 3 months prior to HIV-1 diagnoses.</p></sec><sec id="S11"><title>Analysis of the impact of daily tenofovir disoproxil fumarate on the length of the virus eclipse phase in a macaque model</title><p id="P19">To understand if drug pressure because of daily TDF might increase the length of the virus eclipse phase and alter Poisson-Fitter estimates, we examined data obtained from macaques infected with simian HIV (SHIV) while receiving placebo or daily PrEP with TDF or FTC/TDF. We monitored time to first RNA detection in plasma after a single exposure to a high (1000 TCID<sub>50</sub>) dose of SHIV162p3. These macaques were part of studies assessing how high virus doses affect PrEP efficacy, and received placebo or daily PrEP with TDF [<xref rid="R26" ref-type="bibr">26</xref>] or FTC/TDF.</p></sec><sec id="S12"><title>Phylogenetic analysis</title><p id="P20">Sequences were aligned and edited using Geneious software (version 10.0.9). Nucleotide alignments were prepared using ClustalW; all insertion and deletions were removed from the alignments prior to phylogenetic analysis. Estimates of virus diversity were done by pairwise analysis of individual sequences using the maximum composite likelihood method in MEGA (version 7.0.18), and the results are expressed as number of base substitutions per site. Patterns of <italic toggle="yes">env</italic> diversity in each infection were visualized using the highlighter tool (available at <ext-link xlink:href="https://www.hiv.lanl.gov/content/sequence/HIGHLIGHT/highlighter_top.html" ext-link-type="uri">https://www.hiv.lanl.gov/content/sequence/HIGHLIGHT/highlighter_top.html</ext-link>).</p></sec><sec id="S13"><title>Statistical analysis</title><p id="P21">Medians and interquartile ranges (IQRs) were calculated for virus diversity and plasma HIV-1 RNA concentrations by group (TDF and placebo infections). Statistical differences were evaluated for virus diversity and plasma HIV-1 RNA using the Wilcoxon rank-sum test to compare the TDF and placebo group. The proportion of infections initiated by a single genetic variant in the TDF and placebo groups was compared using the Fisher&#x02019;s exact test. Analyses were completed using SAS version 9.4 (SAS Institute Inc., Cary, North Carolina, USA).</p></sec></sec><sec id="S14"><title>Results</title><sec id="S15"><title>HIV-1 <italic toggle="yes">env</italic> diversity in participants taking daily tenofovir disoproxil fumarate preexposure prophylaxis</title><p id="P22">We attempted to characterize HIV-1 genetic diversity in the 17 participants from BTS that had incident infection while taking TDF PrEP. HIV diversity was investigated at the visit when HIV-1 RNA was first detected in plasma. At this visit, nine participants had detectable TFV in plasma, seven had TFV levels below the limit of quantification, and one (TDF4) did not have sufficient plasma for testing (<xref rid="T1" ref-type="table">Table 1</xref>). Median plasma HIV-1 RNA concentration was 4.2 [interquartile range (IQR)=1.6] log<sub>10</sub> RNA copies/ml. HIV-1 <italic toggle="yes">env</italic> was successfully amplified and sequenced in 15 of the 17 incident infections. For each participant, we generated 10&#x02013;25 <italic toggle="yes">env</italic> sequences by single genome amplification. The median <italic toggle="yes">env</italic> diversity was 0.00126 (IQR = 0.00124) base substitutions per site or 1.26 mutations in 1000 bp sequence. Of the 15 infections with available sequences, 13 (86.7%) were initiated by a single genetic variant. <xref rid="SD1" ref-type="supplementary-material">Supplementary Fig1</xref>, <ext-link xlink:href="http://links.lww.com/QAD/B546" ext-link-type="uri">http://links.lww.com/QAD/B546</ext-link> shows the highlighter plots generated in the 15 infections from the TDF group and illustrates how most of these infections were highly homogeneous. Participants TDF4 and TDF8 had multivariant infection (i.e. <italic toggle="yes">P</italic> value &#x0003c;0.1 denoting divergence from a Poisson distribution). A close evaluation of trial visits in these two participants showed that they missed their regularly scheduled visit during the 5 and 3 years preceding the specimen collection.</p></sec><sec id="S16"><title>Comparison of virus diversity between infections in the tenofovir disoproxil fumarate and placebo groups</title><p id="P23">We next compared virus diversity and frequency of single variant infections among PrEP breakthrough infections and infections in the placebo group (<italic toggle="yes">n</italic> = 16). Eleven of the 16 placebo infections (68.7%) were initiated by a single genetic variant (<italic toggle="yes">P</italic> = 0.22 compared with the TDF group) (<xref rid="T1" ref-type="table">Table 1</xref> and <xref rid="SD1" ref-type="supplementary-material">Supplementary Fig. 2</xref>, <ext-link xlink:href="http://links.lww.com/QAD/B546" ext-link-type="uri">http://links.lww.com/QAD/B546</ext-link>). Median <italic toggle="yes">env</italic> diversity in the placebo group [0.00151 (IQR = 0.00715) base substitutions per site] was similar to that seen in PrEP breakthrough infections [0.001265 (IQR = 0.00124), <italic toggle="yes">P</italic> = 0.71] (<xref rid="F2" ref-type="fig">Fig. 2</xref>). A sub-analysis of <italic toggle="yes">env</italic> diversity limited to participants with single variant infections also showed no differences of virus diversity between the TDF and placebo groups (medians of 0.00122 (IQR = 0.000959) and 0.000571 (0.00145) base substitutions per site, respectively, <italic toggle="yes">P</italic> = 0.56].</p></sec><sec id="S17"><title>Estimates of date of infection in participants assigned to tenofovir disoproxil fumarate or placebo</title><p id="P24">We next calculated the approximate date of infection using the Poisson-Fitter and SPMM tools. We generated reliable estimates of infection duration in all the 13 single variant infections from the TDF group, and in 11 of the 16 placebo participants including two (PL3 and PL10) that were infected with multiple variants (<xref rid="T1" ref-type="table">Table 1</xref>). In the remaining participants, estimates of time since infection were unreliable as the data did not fit the underlying Poisson distribution models as indicated by a low (&#x0003c;0.1 for Poisson-Fitter and &#x0003c;0.05 for SPMM) goodness-of-fit <italic toggle="yes">P</italic> value (<xref rid="T1" ref-type="table">Table 1</xref>). The median time since infection in single variant infections from the TDF group was 47 days (IQR= 35) and was not statistically different from that seen in single-variant placebo infections [18 days (IQR= 44)] (<italic toggle="yes">P</italic> = 0.40). Median time since infection in the four participants that were NAT+ but seronegative was 10.5 days (IQR= 6) compared with 46.5 days (IQR= 37) among the 19 participants that were NAT+ and EIA+ (<italic toggle="yes">P</italic> &#x0003c; 0.01).</p></sec><sec id="S18"><title>Analysis of preexposure prophylaxis adherence diaries at the estimated date of infection</title><p id="P25">We then used PrEP adherence diaries to count the number of TDF doses taken within the 95% confidence interval of the estimated date of infection. <xref rid="F3" ref-type="fig">Figure 3</xref> shows the adherence diaries for each participant with incident infection as well as the number of TDF doses taken within this period of time. This analysis was limited to the 11 participants who took TDF under daily DOT to minimize potential bias from self-reported adherence [<xref rid="R27" ref-type="bibr">27</xref>]. In five of the 11 participants (TDF2, TDF3, TDF6, TDF9, and TDF15), the entire interval estimates of infection fell within periods of 100% adherence according to medication diaries. Participants TDF2, TDF6 and TDF15 were 100% adherent during the 3 months prior to the first RNA-positive visit. Participant TDF3 missed eight TDF doses more than 8 weeks prior to the first RNA-positive visit but was fully adherent during the interval estimate of infection. Participant TDF9 was reported 100% adherent during the estimated date of infection although adherence diaries document several weeks of nonadherence immediately before infection (<xref rid="F3" ref-type="fig">Fig. 3</xref>). Adherence in two other incident infections (TDF11 and TDF12) was also very high according to medication diaries with only a few missed doses recorded immediately before or after the estimated day of infection. Participant TDF11 missed two doses of TDF 4&#x02013;5 days prior to the estimated day of infection, whereas participant TDF12 missed five TDF doses 4&#x02013;5 days before or after the estimated day of infection (<xref rid="F3" ref-type="fig">Fig. 3</xref>). In the remaining four participants (TDF1, TDF5, TDF13, and TDF14), infection occurred during periods of little or no adherence to daily TDF. In two participants (TDF1 and TDF12), TFV was undetectable in plasma at the first NAT+ visit despite reported adherence by DOT.</p></sec><sec id="S19"><title>Impact of daily tenofovir disoproxil fumarate on the length of the virus eclipse phase as defined in a macaque model of infection with simian HIV</title><p id="P26">We investigated in macaques infected with SHIV if drug pressure because of daily TDF might increase the length of the virus eclipse phase and alter Poisson-Fitter estimates. <xref rid="F4" ref-type="fig">Figure 4</xref> shows that time to first RNA detection was 7 days in untreated macaques, and that daily TDF increased the length of the virus eclipse phase to 7&#x02013; 14 days (mean = 11.7; <italic toggle="yes">P</italic> = 0.038). Although significant, the effect was smaller than that observed with daily FTC/ TDF combination (21 days; <italic toggle="yes">P</italic> = 0.015).</p></sec></sec><sec id="S20"><title>Discussion</title><p id="P27">We characterized early HIV-1 <italic toggle="yes">env</italic> sequences in participants with incident HIV-1 infection in a human PrEP trial with daily TDF in order to estimate the date of infection using well established mathematical models of early virus evolution. We sought to relate HIV infections with PrEP pill-taking behavior at the time when infection was most likely to have occurred. Our analysis found that five of the 11 participants tested had an estimated date of infection that fell within periods of 100% adherence as defined by adherence diaries obtained under daily DOT, though interruptions in PrEP adherence were also noted in two of these participants prior to the estimated time of infection. These cases suggest that daily oral TDF at the doses given may not provide complete protection from HIV infection through intravenous exposure. However, it is clear that oral TDF does provide protection given that in a subanalysis of the BTS data including all participants (i.e. those on and not on DOT), high adherence levels were associated with a 83.5% reduction in the risk of infection [<xref rid="R28" ref-type="bibr">28</xref>]. Alternative interpretations of our data can be made. Data in the adherence diaries under DOT may not have accurately reflected drug exposure in some cases, either because of data entry errors or other factors. For instance, we noted two participants (TDF1 and TDF12) with undetectable TFV in plasma at a visit that had reported adherence by DOT. In addition, substantial errors in our estimates of the date of infection may have obscured true infection times during periods of poor regimen adherence. Such errors may be more pronounced among those participants that had a limited number of sequences generated by SGA.</p><p id="P28">We found that TFV did not have a significant effect on HIV <italic toggle="yes">env</italic> diversity at the first NAT+ sample, as the overall diversity in PrEP breakthrough infections was comparable to that seen in participants receiving placebo. This observation suggests that drug selective pressure in the reverse transcriptase originating from exposure to daily TDF during undiagnosed infection may not significantly affect HIV-1 <italic toggle="yes">env</italic> evolution, though additional studies with larger numbers of infections may be needed. Unfortunately, we did not have longitudinal specimens from macaques infected with SHIV during daily TDF to support this observation. However, estimates of infection duration in BTS participants as defined by <italic toggle="yes">env</italic> diversity correlated well with Fiebig staging as also found in other studies [<xref rid="R13" ref-type="bibr">13</xref>,<xref rid="R14" ref-type="bibr">14</xref>,<xref rid="R19" ref-type="bibr">19</xref>,<xref rid="R20" ref-type="bibr">20</xref>]; these estimates were 11 days in participants in Fiebig stages I/II (NAT+, antibody negative) compared with 47 days in those that were both nucleic acid testing (NAT) and antibody positive.</p><p id="P29">Our molecular approach to estimate time since infection has the potential to be applied to other PrEP modalities including topical products, implants and long-acting injectable formulations, where the availability of infection estimates may be particularly useful for defining drug concentrations associated with breakthrough infection. However, such analysis will require careful validation of Poisson-Fitter models and considerations on how more potent regimens can impact HIV-1 evolution and length of the virus eclipse phase. We noted that daily FTC/TDF in macaques could lengthen the virus eclipse phase from 7 to 21 days. In an earlier study, continued exposure of macaques to FTC/DTF was also associated with a reduction in <italic toggle="yes">env</italic> diversification [<xref rid="R29" ref-type="bibr">29</xref>]. Thus, estimations of time since infection with more potent drugs/drug combinations or novel PrEP modalities may require prior validation of Poisson models using for instance animal models of PrEP where exposure is done under controlled conditions and specimens collected frequently enough to precisely define acute infection dynamics. In the context of objective adherence measures, the Poisson tools may potentially help evaluate biological efficacy in real time, and inform decision making on whether a PrEP trial should continue or not.</p><p id="P30">Our study has several limitations. First, despite regular monitoring, it is possible that errors occurred during DOT study drug administration, data collection, and data entry. This might for instance explain the lack of detectable TFV in plasma at the first NAT-positive sample in participants TDF1 and TDF12 who were reported as adherent in that visit, although testing error or incomplete drug absorption/metabolism might also explain the findings. Second, it is possible that the administration of antiretroviral therapy lengthened the viral eclipse phase, affecting the accuracy of the estimated date of infection. Although not conclusive, our results in rhesus macaques infected rectally with simian HIV demonstrated only modest eclipse phase changes on the order of 4 days, suggesting that this effect may be minimal. However, this modest effect might be sufficient to explain infection in participant TDF9 that was reported as 100% adherent at the estimated date of infection but was nonadherent for several weeks immediately before. If this is the case, this participant would be erroneously reported as 100% adherent in our analysis.</p><p id="P31">In conclusion, we applied molecular tools to estimate the day of infection among participants from a human PrEP trial with daily TDF, and mapped these estimates with pill-taking behaviors. Using this approach, we found that breakthrough infections may occur among potentially highly adherent PWID taking daily TDF PrEP. This finding is consistent with the overall biological efficacy of daily TDF against parenteral HIV-1 transmission being less than 100%, although we cannot exclude that some of the infections might have occurred through the sexual route. As new methods to measure daily adherence are developed and new PrEP regimens are evaluated in humans, our molecular approach provides a new tool that can help to better define the biological efficacy of PrEP.</p></sec><sec sec-type="supplementary-material" id="SM1"><title>Supplementary Material</title><supplementary-material id="SD1" position="float" content-type="local-data"><label>2</label><media xlink:href="NIHMS1975648-supplement-2.pdf" id="d66e567" position="anchor"/></supplementary-material></sec></body><back><ack id="S21"><title>Acknowledgements</title><p id="P32">We thank Bill Switzer for helping with the analysis of recombination, and Chuong T. Dinh for his assistance in measuring TFV concentrations in some of the plasma specimens.</p><sec id="S22"><title>Funding:</title><p id="P33">CDC intramural funds.</p></sec></ack><fn-group><fn id="FN3"><p id="P34">Disclaimer: The findings and conclusions of this manuscript are those of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention.</p></fn><fn fn-type="COI-statement" id="FN4"><p id="P35">Conflicts of interest</p><p id="P36">J.G.G.-L. and W.H. are named on US Government patents on &#x02018;Inhibition of HIV infection through chemoprophylaxis&#x02019;, and on patent applications on &#x02018;HIV post-exposure prophylaxis&#x02019; and &#x02018;HIV pre-exposure prophylaxis&#x02019;.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1.</label><mixed-citation publication-type="webpage"><source>HIV/AIDS fact sheet World Health organization</source> [<date-in-citation>updated 2017</date-in-citation>]. Available at: <comment><ext-link xlink:href="http://www.who.int/mediacentre/factsheets/fs360/en/" ext-link-type="uri">http://www.who.int/mediacentre/factsheets/fs360/en/</ext-link>.</comment> [<date-in-citation>Accessed 10 July 2019</date-in-citation>]</mixed-citation></ref><ref id="R2"><label>2.</label><mixed-citation publication-type="journal"><name><surname>Riddell</surname><given-names>J</given-names></name>, <name><surname>Amico</surname><given-names>KR</given-names></name>, <name><surname>Mayer</surname><given-names>KH</given-names></name>. <article-title>HIV preexposure prophylaxis: a review</article-title>. <source>JAMA</source>
<year>2018</year>; <volume>319</volume>:<fpage>1261</fpage>&#x02013;<lpage>1268</lpage>.<pub-id pub-id-type="pmid">29584848</pub-id>
</mixed-citation></ref><ref id="R3"><label>3.</label><mixed-citation publication-type="journal"><name><surname>Grant</surname><given-names>RM</given-names></name>, <name><surname>Lama</surname><given-names>JR</given-names></name>, <name><surname>Anderson</surname><given-names>PL</given-names></name>, <name><surname>McMahan</surname><given-names>V</given-names></name>, <name><surname>Liu</surname><given-names>AY</given-names></name>, <name><surname>Vargas</surname><given-names>L</given-names></name>, <etal/>, <article-title>the iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men</article-title>. <source>N Engl J Med</source>
<year>2010</year>; <volume>363</volume>:<fpage>2587</fpage>&#x02013;<lpage>2599</lpage>.<pub-id pub-id-type="pmid">21091279</pub-id>
</mixed-citation></ref><ref id="R4"><label>4.</label><mixed-citation publication-type="journal"><name><surname>Baeten</surname><given-names>JM</given-names></name>, <name><surname>Donnell</surname><given-names>D</given-names></name>, <name><surname>Ndase</surname><given-names>P</given-names></name>, <name><surname>Mugo</surname><given-names>NR</given-names></name>, <name><surname>Campbell</surname><given-names>JD</given-names></name>, <name><surname>Wangisi</surname><given-names>J</given-names></name>, <etal/>, <article-title>the Partners PrEP Study Team. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women</article-title>. <source>N Engl J Med</source>
<year>2012</year>; <volume>367</volume>:<fpage>399</fpage>&#x02013;<lpage>410</lpage>.<pub-id pub-id-type="pmid">22784037</pub-id>
</mixed-citation></ref><ref id="R5"><label>5.</label><mixed-citation publication-type="journal"><name><surname>Thigpen</surname><given-names>MC</given-names></name>, <name><surname>Kebaabetswe</surname><given-names>PM</given-names></name>, <name><surname>Paxton</surname><given-names>LA</given-names></name>, <name><surname>Smith</surname><given-names>DK</given-names></name>, <name><surname>Rose</surname><given-names>CE</given-names></name>, <name><surname>Segolodi</surname><given-names>TM</given-names></name>, <etal/>, <article-title>TDF2 Study Group. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana</article-title>. <source>N Engl J Med</source>
<year>2012</year>; <volume>367</volume>:<fpage>423</fpage>&#x02013;<lpage>434</lpage>.<pub-id pub-id-type="pmid">22784038</pub-id>
</mixed-citation></ref><ref id="R6"><label>6.</label><mixed-citation publication-type="journal"><name><surname>Choopanya</surname><given-names>K</given-names></name>, <name><surname>Martin</surname><given-names>M</given-names></name>, <name><surname>Suntharasamai</surname><given-names>P</given-names></name>, <name><surname>Sangkum</surname><given-names>U</given-names></name>, <name><surname>Mock</surname><given-names>PA</given-names></name>, <name><surname>Leethochawalit</surname><given-names>M</given-names></name>, <etal/>, <article-title>Bangkok Tenofovir Study Group. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial</article-title>. <source>Lancet</source>
<year>2013</year>; <volume>381</volume>:<fpage>2083</fpage>&#x02013;<lpage>2090</lpage>.<pub-id pub-id-type="pmid">23769234</pub-id>
</mixed-citation></ref><ref id="R7"><label>7.</label><mixed-citation publication-type="book"><name><surname>Marrazzo</surname><given-names>J</given-names></name>, <name><surname>Ramjee</surname><given-names>G</given-names></name>, <name><surname>Nair</surname><given-names>G</given-names></name>, <name><surname>Palanee</surname><given-names>T</given-names></name>, <name><surname>Mkhize</surname><given-names>B</given-names></name>, <name><surname>Nakabiito</surname><given-names>C</given-names></name>, <etal/>
<part-title>for the VOICE study team. Preexposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine, or vaginal tenofovir gel in the VOICE study (MTN 003)</part-title>. <source>Conference on Retroviruses and Opportunistic Infections</source>. <publisher-loc>Atlanta</publisher-loc>; <year>2013</year>.</mixed-citation></ref><ref id="R8"><label>8.</label><mixed-citation publication-type="journal"><name><surname>Van Damme</surname><given-names>L</given-names></name>, <name><surname>Corneli</surname><given-names>A</given-names></name>, <name><surname>Ahmed</surname><given-names>K</given-names></name>, <name><surname>Agot</surname><given-names>K</given-names></name>, <name><surname>Lombaard</surname><given-names>J</given-names></name>, <name><surname>Kapiga</surname><given-names>S</given-names></name>, <etal/>, <article-title>FEM-PrEP Study Group. Preexposure prophylaxis for HIV infection among African women</article-title>. <source>N Engl J Med</source>
<year>2012</year>; <volume>367</volume>:<fpage>411</fpage>&#x02013;<lpage>422</lpage>.<pub-id pub-id-type="pmid">22784040</pub-id>
</mixed-citation></ref><ref id="R9"><label>9.</label><mixed-citation publication-type="journal"><name><surname>Anderson</surname><given-names>PL</given-names></name>, <name><surname>Glidden</surname><given-names>DV</given-names></name>, <name><surname>Liu</surname><given-names>A</given-names></name>, <name><surname>Buchbinder</surname><given-names>S</given-names></name>, <name><surname>Lama</surname><given-names>JR</given-names></name>, <name><surname>Guanira</surname><given-names>JV</given-names></name>, <etal/>, <article-title>iPrEx Study Team. Emtricitabine-tenofovir concentrations and preexposure prophylaxis efficacy in men who have sex with men</article-title>. <source>Sci Transl Med</source>
<year>2012</year>; <volume>4</volume>:151ra125.</mixed-citation></ref><ref id="R10"><label>10.</label><mixed-citation publication-type="journal"><name><surname>Castillo-Mancilla</surname><given-names>JR</given-names></name>, <name><surname>Zheng</surname><given-names>JH</given-names></name>, <name><surname>Rower</surname><given-names>JE</given-names></name>, <name><surname>Meditz</surname><given-names>A</given-names></name>, <name><surname>Gardner</surname><given-names>EM</given-names></name>, <name><surname>Predhomme</surname><given-names>J</given-names></name>, <etal/>
<article-title>Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure</article-title>. <source>AIDS Res Hum Retroviruses</source>
<year>2013</year>; <volume>29</volume>:<fpage>384</fpage>&#x02013;<lpage>390</lpage>.<pub-id pub-id-type="pmid">22935078</pub-id>
</mixed-citation></ref><ref id="R11"><label>11.</label><mixed-citation publication-type="journal"><name><surname>Anderson</surname><given-names>PL</given-names></name>, <name><surname>Liu</surname><given-names>AY</given-names></name>, <name><surname>Castillo-Mancilla</surname><given-names>JR</given-names></name>, <name><surname>Gardner</surname><given-names>EM</given-names></name>, <name><surname>Seifert</surname><given-names>SM</given-names></name>, <name><surname>McHugh</surname><given-names>C</given-names></name>, <etal/>
<article-title>Intracellular tenofovir-diphosphate and emtricitabine-triphosphate in dried blood spots following directly observed therapy</article-title>. <source>Antimicrob Agents Chemother</source>
<year>2017</year>; <volume>62</volume>:e01710&#x02013;e01717.</mixed-citation></ref><ref id="R12"><label>12.</label><mixed-citation publication-type="journal"><name><surname>Dimitrov</surname><given-names>DT</given-names></name>, <name><surname>Ma&#x002c6;sse</surname><given-names>BR</given-names></name>, <name><surname>Donnell</surname><given-names>D</given-names></name>. <article-title>PrEP adherence patterns strongly affect individual HIV risk and observed efficacy in randomized clinical trials</article-title>. <source>J Acquir Immune Defic Syndr</source>
<year>2016</year>; <volume>72</volume>:<fpage>444</fpage>&#x02013;<lpage>451</lpage>.<pub-id pub-id-type="pmid">26990823</pub-id>
</mixed-citation></ref><ref id="R13"><label>13.</label><mixed-citation publication-type="journal"><name><surname>Giorgi</surname><given-names>EE</given-names></name>, <name><surname>Funkhouser</surname><given-names>B</given-names></name>, <name><surname>Athreya</surname><given-names>G</given-names></name>, <name><surname>Perelson</surname><given-names>AS</given-names></name>, <name><surname>Korber</surname><given-names>BT</given-names></name>, <name><surname>Bhattacharya</surname><given-names>T</given-names></name>. <article-title>Estimating time since infection in early homogeneous HIV samples using a poisson model</article-title>. <source>BMC Bioinformatics</source>
<year>2010</year>; <volume>11</volume>:<fpage>532</fpage>.<pub-id pub-id-type="pmid">20973976</pub-id>
</mixed-citation></ref><ref id="R14"><label>14.</label><mixed-citation publication-type="journal"><name><surname>Love</surname><given-names>TM</given-names></name>, <name><surname>Park</surname><given-names>SY</given-names></name>, <name><surname>Giorgi</surname><given-names>EE</given-names></name>, <name><surname>Mack</surname><given-names>WJ</given-names></name>, <name><surname>Perelson</surname><given-names>AS</given-names></name>, <name><surname>Lee</surname><given-names>HY</given-names></name>. <article-title>SPMM: estimating infection duration of multivariant HIV-1 infections</article-title>. <source>Bioinformatics</source>
<year>2016</year>; <volume>32</volume>:<fpage>1308</fpage>&#x02013;<lpage>1315</lpage>.<pub-id pub-id-type="pmid">26722117</pub-id>
</mixed-citation></ref><ref id="R15"><label>15.</label><mixed-citation publication-type="journal"><name><surname>Ribeiro</surname><given-names>RM</given-names></name>, <name><surname>Qin</surname><given-names>L</given-names></name>, <name><surname>Chavez</surname><given-names>LL</given-names></name>, <name><surname>Li</surname><given-names>D</given-names></name>, <name><surname>Self</surname><given-names>SG</given-names></name>, <name><surname>Perelson</surname><given-names>AS</given-names></name>. <article-title>Estimation of the initial viral growth rate and basic reproductive number during acute HIV-1 infection</article-title>. <source>J Virol</source>
<year>2010</year>; <volume>84</volume>:<fpage>6096</fpage>&#x02013;<lpage>6102</lpage>.<pub-id pub-id-type="pmid">20357090</pub-id>
</mixed-citation></ref><ref id="R16"><label>16.</label><mixed-citation publication-type="journal"><name><surname>Markowitz</surname><given-names>M</given-names></name>, <name><surname>Louie</surname><given-names>M</given-names></name>, <name><surname>Hurley</surname><given-names>A</given-names></name>, <name><surname>Sun</surname><given-names>E</given-names></name>, <name><surname>Di Mascio</surname><given-names>M</given-names></name>, <name><surname>Perelson</surname><given-names>AS</given-names></name>, <name><surname>Ho</surname><given-names>DD</given-names></name>. <article-title>A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo</article-title>. <source>J Virol</source>
<year>2003</year>; <volume>77</volume>:<fpage>5037</fpage>&#x02013;<lpage>5038</lpage>.<pub-id pub-id-type="pmid">12663814</pub-id>
</mixed-citation></ref><ref id="R17"><label>17.</label><mixed-citation publication-type="journal"><name><surname>Mansky</surname><given-names>LM</given-names></name>, <name><surname>Temin</surname><given-names>HM</given-names></name>. <article-title>Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase</article-title>. <source>J Virol</source>
<year>1995</year>; <volume>69</volume>:<fpage>5087</fpage>&#x02013;<lpage>5094</lpage>.<pub-id pub-id-type="pmid">7541846</pub-id>
</mixed-citation></ref><ref id="R18"><label>18.</label><mixed-citation publication-type="journal"><name><surname>Stafford</surname><given-names>MA</given-names></name>, <name><surname>Corey</surname><given-names>L</given-names></name>, <name><surname>Cao</surname><given-names>Y</given-names></name>, <name><surname>Daar</surname><given-names>ES</given-names></name>, <name><surname>Ho</surname><given-names>DD</given-names></name>, <name><surname>Perelson</surname><given-names>AS</given-names></name>. <article-title>Modeling plasma virus concentration during primary HIV infection</article-title>. <source>J Theor Biol</source>
<year>2000</year>; <volume>203</volume>:<fpage>285</fpage>&#x02013;<lpage>301</lpage>.<pub-id pub-id-type="pmid">10716909</pub-id>
</mixed-citation></ref><ref id="R19"><label>19.</label><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>HY</given-names></name>, <name><surname>Giorgi</surname><given-names>EE</given-names></name>, <name><surname>Keele</surname><given-names>BF</given-names></name>, <name><surname>Gaschen</surname><given-names>B</given-names></name>, <name><surname>Athreya</surname><given-names>GS</given-names></name>, <name><surname>Salazar-Gonzalez</surname><given-names>JF</given-names></name>, <etal/>
<article-title>Modeling sequence evolution in acute HIV-1 infection</article-title>. <source>J Theor Biol</source>
<year>2009</year>; <volume>261</volume>:<fpage>341</fpage>&#x02013;<lpage>360</lpage>.<pub-id pub-id-type="pmid">19660475</pub-id>
</mixed-citation></ref><ref id="R20"><label>20.</label><mixed-citation publication-type="journal"><name><surname>Keele</surname><given-names>BF</given-names></name>, <name><surname>Giorgi</surname><given-names>EE</given-names></name>, <name><surname>Salazar-Gonzalez</surname><given-names>JF</given-names></name>, <name><surname>Decker</surname><given-names>JM</given-names></name>, <name><surname>Pham</surname><given-names>KT</given-names></name>, <name><surname>Salazar</surname><given-names>MG</given-names></name>, <etal/>
<article-title>Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection</article-title>. <source>Proc Natl Acad Sci U S A</source>
<year>2008</year>; <volume>105</volume>:<fpage>7552</fpage>&#x02013;<lpage>7557</lpage>.<pub-id pub-id-type="pmid">18490657</pub-id>
</mixed-citation></ref><ref id="R21"><label>21.</label><mixed-citation publication-type="journal"><name><surname>Suntharasamai</surname><given-names>P</given-names></name>, <name><surname>Martin</surname><given-names>M</given-names></name>, <name><surname>Choopanya</surname><given-names>K</given-names></name>, <name><surname>Vanichseni</surname><given-names>S</given-names></name>, <name><surname>Sangkum</surname><given-names>U</given-names></name>, <name><surname>Tararut</surname><given-names>P</given-names></name>, <etal/>
<article-title>Assessment of oral fluid HIV test performance in an HIV pre-exposure prophylaxis trial in Bangkok, Thailand</article-title>. <source>PLoS One</source>
<year>2015</year>; <volume>10</volume>:e0145859.</mixed-citation></ref><ref id="R22"><label>22.</label><mixed-citation publication-type="journal"><name><surname>Kuklenyik</surname><given-names>Z</given-names></name>, <name><surname>Martin</surname><given-names>A</given-names></name>, <name><surname>Pau</surname><given-names>CP</given-names></name>, <name><surname>Garcia-Lerma</surname><given-names>JG</given-names></name>, <name><surname>Heneine</surname><given-names>W</given-names></name>, <name><surname>Pirkle</surname><given-names>JL</given-names></name>, <name><surname>Barr</surname><given-names>JR</given-names></name>. <article-title>Effect of mobile phase pH and organic content on LC-MS analysis of nucleoside and nucleotide HIV reverse transcriptase inhibitors</article-title>. <source>J Chromatogr Sci</source>
<year>2009</year>; <volume>47</volume>:<fpage>365</fpage>&#x02013;<lpage>372</lpage>.<pub-id pub-id-type="pmid">19476704</pub-id>
</mixed-citation></ref><ref id="R23"><label>23.</label><mixed-citation publication-type="journal"><name><surname>Boonchawalit</surname><given-names>S</given-names></name>, <name><surname>Jullaksorn</surname><given-names>D</given-names></name>, <name><surname>Uttiyoung</surname><given-names>J</given-names></name>, <name><surname>Yowang</surname><given-names>A</given-names></name>, <name><surname>Krathong</surname><given-names>N</given-names></name>, <name><surname>Chautrakul</surname><given-names>S</given-names></name>, <etal/>
<article-title>Molecular evolution of HIV-1 CRF01_AE Env in Thai patients</article-title>. <source>PLoS One</source>
<year>2011</year>; <volume>6</volume>:e27098.</mixed-citation></ref><ref id="R24"><label>24.</label><mixed-citation publication-type="journal"><name><surname>Jesus Salazar-Gonzalez</surname><given-names>Kimmy Pham</given-names></name>, <name><surname>Keele</surname><given-names>Brandon</given-names></name><article-title>, David McPherson. Standard operating procedure for: single genome amplification of HIV-1 envelope</article-title>. <source>In. Edited by (CHAVI) CHAVI: Molecular Biology and Sequencin Core: University of Alabama at Birmingham</source>; <year>2007</year>.</mixed-citation></ref><ref id="R25"><label>25.</label><mixed-citation publication-type="journal"><name><surname>Salazar-Gonzalez</surname><given-names>JF</given-names></name>, <name><surname>Bailes</surname><given-names>E</given-names></name>, <name><surname>Pham</surname><given-names>KT</given-names></name>, <name><surname>Salazar</surname><given-names>MG</given-names></name>, <name><surname>Guffey</surname><given-names>MB</given-names></name>, <name><surname>Keele</surname><given-names>BF</given-names></name>, <etal/>
<article-title>Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing</article-title>. <source>J Virol</source>
<year>2008</year>; <volume>82</volume>:<fpage>3952</fpage>&#x02013;<lpage>3970</lpage>.<pub-id pub-id-type="pmid">18256145</pub-id>
</mixed-citation></ref><ref id="R26"><label>26.</label><mixed-citation publication-type="journal"><name><surname>Subbarao</surname><given-names>S</given-names></name>, <name><surname>Ramos</surname><given-names>A</given-names></name>, <name><surname>Kim</surname><given-names>C</given-names></name>, <name><surname>Adams</surname><given-names>D</given-names></name>, <name><surname>Monsour</surname><given-names>M</given-names></name>, <name><surname>Butera</surname><given-names>S</given-names></name>, <etal/>
<article-title>Direct stringency comparison of two macaque models (single-high vs. repeat-low) for mucosal HIV transmission using an identical anti-HIV chemoprophylaxis intervention</article-title>. <source>J Med Primatol</source>
<year>2007</year>; <volume>36</volume>:<fpage>238</fpage>&#x02013;<lpage>243</lpage>.<pub-id pub-id-type="pmid">17669212</pub-id>
</mixed-citation></ref><ref id="R27"><label>27.</label><mixed-citation publication-type="journal"><name><surname>Amico</surname><given-names>KR</given-names></name>, <name><surname>Marcus</surname><given-names>JL</given-names></name>, <name><surname>McMahan</surname><given-names>V</given-names></name>, <name><surname>Liu</surname><given-names>A</given-names></name>, <name><surname>Koester</surname><given-names>KA</given-names></name>, <name><surname>Goicochea</surname><given-names>P</given-names></name>, <etal/>
<article-title>Study product adherence measurement in the iPrEx placebo-controlled trial: concordance with drug detection</article-title>. <source>J Acquir Immune Defic Syndr</source>
<year>2014</year>; <volume>66</volume>:<fpage>530</fpage>&#x02013;<lpage>537</lpage>.<pub-id pub-id-type="pmid">24853306</pub-id>
</mixed-citation></ref><ref id="R28"><label>28.</label><mixed-citation publication-type="journal"><name><surname>Martin</surname><given-names>M</given-names></name>, <name><surname>Vanichseni</surname><given-names>S</given-names></name>, <name><surname>Suntharasamai</surname><given-names>P</given-names></name>, <name><surname>Sangkum</surname><given-names>U</given-names></name>, <name><surname>Mock</surname><given-names>PA</given-names></name>, <name><surname>Leethochawalit</surname><given-names>M</given-names></name>, <etal/>, <article-title>Bangkok Tenofovir Study Group. The impact of adherence to preexposure prophylaxis on the risk of HIV infection among people who inject drugs</article-title>. <source>AIDS</source>
<year>2015</year>; <volume>29</volume>:<fpage>819</fpage>&#x02013;<lpage>824</lpage>.<pub-id pub-id-type="pmid">25985403</pub-id>
</mixed-citation></ref><ref id="R29"><label>29.</label><mixed-citation publication-type="journal"><name><surname>Zheng</surname><given-names>Q</given-names></name>, <name><surname>Ruone</surname><given-names>S</given-names></name>, <name><surname>Switzer</surname><given-names>WM</given-names></name>, <name><surname>Heneine</surname><given-names>W</given-names></name>, <name><surname>Garcia-Lerma</surname><given-names>JG</given-names></name>. <article-title>Limited SHIV env diversification in macaques failing oral antiretroviral preexposure prophylaxis</article-title>. <source>Retrovirology</source>
<year>2012</year>; <volume>9</volume>:<fpage>40</fpage>.<pub-id pub-id-type="pmid">22571771</pub-id>
</mixed-citation></ref></ref-list></back><floats-group><fig position="float" id="F1"><label>Fig. 1.</label><caption><title>Computation of number of tenofovir disoproxil fumarate doses taken within the estimated date of infection.</title><p id="P37">The diversity structure of the virus population (highlighter plot) defined at the first nucleic acid testing positive (NAT+) sample using single genome amplification and sequence analysis is used to estimate date of infection using the Poisson Fitter or Shifted Poisson Mixture Model (SPMM). Estimates of date of infection are then integrated with adherence maps generated under daily directly observed therapy to compute the number of TDF doses taken within this period of time. One square represents 1 day (red = missed TDF dose; blue = TDF dose taken). Orange circle denotes the last negative EIA or NAT specimen. The estimated time of infection (and 95% CI) is indicated with a green line. The highlighter plot illustrates the changes observed in each individual sequence relative to the consensus (A: green, T: red, G: orange, C: light blue, IUPAC: dark blue, gaps: gray, circle: APOBEC signatures, diamond: G to A conversions). EIA, enzyme immunoassay; NAT, nucleic acid testing; TDF, tenofovir disoproxil fumarate.</p></caption><graphic xlink:href="nihms-1975648-f0001" position="float"/></fig><fig position="float" id="F2"><label>Fig. 2.</label><caption><title>HIV <italic toggle="yes">env</italic> diversity in incident infections from the Bangkok Tenofovir Study (BTS) with daily tenofovir disoproxil fumarate.</title><p id="P38">Diversity was measured when HIV RNA was detected in plasma for the first time. This visit coincided with the seroconversion visit in 14 of the 17 infections in the TDF group, and in 15 of the 16 infections in the placebo group. Estimates of diversity were determined by measuring mean pairwise distances between individual sequences from each participant. Results are expressed as number of nucleotide substitutions per site. Horizontal lines denote median values for each group.</p></caption><graphic xlink:href="nihms-1975648-f0002" position="float"/></fig><fig position="float" id="F3"><label>Fig. 3.</label><caption><title>Analysis of pill taking behavior at the estimated time of infection.</title><p id="P39">The estimated infection time (and 95% CI) is indicated with a green line. Adherence diaries obtained under daily directly observed therapy (horizontal lines) were used to manually count the number of missed TDF doses within this period of time. One square represents 1 day (red = missed TDF dose; blue = TDF dose taken). Each block represents 1 month. Orange circle denotes the last negative EIA or NAT specimen. CI, confidence interval; TDF, tenofovir disoproxil fumarate.</p></caption><graphic xlink:href="nihms-1975648-f0003" position="float"/></fig><fig position="float" id="F4"><label>Fig. 4.</label><caption><title>Effect of preexposure prophylaxis with tenofovir disoproxil fumarate or emtricitabine/tenofovir disoproxil fumarate on the length of the virus eclipse phase in macaques infected with simian HIV.</title><p id="P40">These macaques were part of studies assessing how high virus doses affect PrEP efficacy, and received placebo or daily PrEP with TDF [<xref rid="R26" ref-type="bibr">26</xref>] or FTC/TDF. Animals were exposed to a single high (1000 TCID50) dose of a SHIV162p3 isolate containing the HIV-1 envelope, and received clinically equivalent doses of TDF (22 mg/kg) or a combination of TDF (22 mg/kg) and FTC (20 mg/kg). Treatment was initiated 7 days prior to SHIV exposure and stopped 28 days after virus inoculation. (a) Time for SHIV RNA detection in plasma. (b) Impact of TDF or FTC/TDF on the length of the virus eclipse phase as defined by RNA detection in plasma. Time of RNA detection increased from 7 days in untreated animals (<italic toggle="yes">n</italic> = 10), to 11.7 in animals receiving daily TDF (<italic toggle="yes">n</italic> = 3) and 21 days in animals receiving daily FTC/TDF ([<xref rid="R26" ref-type="bibr">26</xref>] and unpublished observation). FTC, emtricitabine; PrEP, preexposure prophylaxis; SHIV, simian HIV; TDF, tenofovir disoproxil fumarate.</p></caption><graphic xlink:href="nihms-1975648-f0004" position="float"/></fig><table-wrap position="float" id="T1" orientation="landscape"><label>Table 1.</label><caption><p id="P41">Characteristics of the study population and estimates of time since infection in 33 participants from the Bangkok Tenofovir Study trial with daily tenofovir disoproxil fumarate who had incident HIV-1 infection.</p></caption><table frame="hsides" rules="none"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Group</th><th align="center" valign="bottom" rowspan="1" colspan="1">Sex</th><th align="left" valign="bottom" rowspan="1" colspan="1">Visit</th><th align="center" valign="bottom" rowspan="1" colspan="1">Plasma HIV RNA (copies/ml)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Plasma TFV (ng/ml)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Number of <italic toggle="yes">env</italic> sequences</th><th align="center" valign="bottom" rowspan="1" colspan="1">Number of base substitutions per site</th><th align="center" valign="bottom" rowspan="1" colspan="1">Number of founder viruses</th><th align="center" valign="bottom" rowspan="1" colspan="1">Time since infection (95% CI)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Goodness of fit <italic toggle="yes">P</italic> value<sup><xref rid="TFN2" ref-type="table-fn">a</xref>,<xref rid="TFN3" ref-type="table-fn">b</xref></sup></th></tr><tr><th colspan="10" align="center" valign="top" rowspan="1">
<hr/>
</th></tr></thead><tbody><tr><td colspan="10" align="left" valign="top" rowspan="1">TDF group</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;TDF1</td><td align="center" valign="top" rowspan="1" colspan="1">M</td><td align="left" valign="top" rowspan="1" colspan="1">NAT FP/EIA+</td><td align="right" valign="top" rowspan="1" colspan="1">434</td><td align="center" valign="top" rowspan="1" colspan="1">BLQ</td><td align="center" valign="top" rowspan="1" colspan="1">21</td><td align="center" valign="top" rowspan="1" colspan="1">0.0016570</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="right" valign="top" rowspan="1" colspan="1">52 (33&#x02013;71)</td><td align="center" valign="top" rowspan="1" colspan="1">0.89</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;TDF2</td><td align="center" valign="top" rowspan="1" colspan="1">M</td><td align="left" valign="top" rowspan="1" colspan="1">NAT FP</td><td align="right" valign="top" rowspan="1" colspan="1">675 000</td><td align="center" valign="top" rowspan="1" colspan="1">288</td><td align="center" valign="top" rowspan="1" colspan="1">22</td><td align="center" valign="top" rowspan="1" colspan="1">0.0001905</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="right" valign="top" rowspan="1" colspan="1">9 (1&#x02013;17)</td><td align="center" valign="top" rowspan="1" colspan="1">0.70</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;TDF3</td><td align="center" valign="top" rowspan="1" colspan="1">M</td><td align="left" valign="top" rowspan="1" colspan="1">NAT FP</td><td align="right" valign="top" rowspan="1" colspan="1">36 100</td><td align="center" valign="top" rowspan="1" colspan="1">182</td><td align="center" valign="top" rowspan="1" colspan="1">22</td><td align="center" valign="top" rowspan="1" colspan="1">0.0004545</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="right" valign="top" rowspan="1" colspan="1">8 (1&#x02013;16)</td><td align="center" valign="top" rowspan="1" colspan="1">0.70</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;TDF4</td><td align="center" valign="top" rowspan="1" colspan="1">M</td><td align="left" valign="top" rowspan="1" colspan="1">NAT FP/EIA+</td><td align="right" valign="top" rowspan="1" colspan="1">9671</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">20</td><td align="center" valign="top" rowspan="1" colspan="1">0.0323300</td><td align="center" valign="top" rowspan="1" colspan="1">18</td><td align="right" valign="top" rowspan="1" colspan="1">31 (15&#x02013;49)</td><td align="center" valign="top" rowspan="1" colspan="1">0.00</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;TDF5</td><td align="center" valign="top" rowspan="1" colspan="1">M</td><td align="left" valign="top" rowspan="1" colspan="1">NAT FP</td><td align="right" valign="top" rowspan="1" colspan="1">536 799</td><td align="center" valign="top" rowspan="1" colspan="1">BLQ</td><td align="center" valign="top" rowspan="1" colspan="1">18</td><td align="center" valign="top" rowspan="1" colspan="1">0.0005556</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="right" valign="top" rowspan="1" colspan="1">15 (1&#x02013;30)</td><td align="center" valign="top" rowspan="1" colspan="1">0.42</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;TDF6</td><td align="center" valign="top" rowspan="1" colspan="1">M</td><td align="left" valign="top" rowspan="1" colspan="1">NAT FP/EIA+</td><td align="right" valign="top" rowspan="1" colspan="1">61 397</td><td align="center" valign="top" rowspan="1" colspan="1">BLQ</td><td align="center" valign="top" rowspan="1" colspan="1">22</td><td align="center" valign="top" rowspan="1" colspan="1">0.0012170</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="right" valign="top" rowspan="1" colspan="1">51 (31&#x02013;70)</td><td align="center" valign="top" rowspan="1" colspan="1">0.77</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;TDF7</td><td align="center" valign="top" rowspan="1" colspan="1">M</td><td align="left" valign="top" rowspan="1" colspan="1">NAT FP/EIA+</td><td align="right" valign="top" rowspan="1" colspan="1">1930</td><td align="center" valign="top" rowspan="1" colspan="1">60</td><td align="center" valign="top" rowspan="1" colspan="1">18</td><td align="center" valign="top" rowspan="1" colspan="1">0.0013660</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="right" valign="top" rowspan="1" colspan="1">50 (32&#x02013;68)</td><td align="center" valign="top" rowspan="1" colspan="1">0.82</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;TDF8</td><td align="center" valign="top" rowspan="1" colspan="1">M</td><td align="left" valign="top" rowspan="1" colspan="1">NAT FP/EIA+</td><td align="right" valign="top" rowspan="1" colspan="1">131 689</td><td align="center" valign="top" rowspan="1" colspan="1">BLQ</td><td align="center" valign="top" rowspan="1" colspan="1">18</td><td align="center" valign="top" rowspan="1" colspan="1">0.0126900</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="right" valign="top" rowspan="1" colspan="1">382 (323&#x02013;441)</td><td align="center" valign="top" rowspan="1" colspan="1">0.00</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;TDF9</td><td align="center" valign="top" rowspan="1" colspan="1">M</td><td align="left" valign="top" rowspan="1" colspan="1">NAT FP/EIA+</td><td align="right" valign="top" rowspan="1" colspan="1">5530</td><td align="center" valign="top" rowspan="1" colspan="1">104</td><td align="center" valign="top" rowspan="1" colspan="1">17</td><td align="center" valign="top" rowspan="1" colspan="1">0.0003529</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="right" valign="top" rowspan="1" colspan="1">16 (7&#x02013;25)</td><td align="center" valign="top" rowspan="1" colspan="1">0.65</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;TDF10</td><td align="center" valign="top" rowspan="1" colspan="1">M</td><td align="left" valign="top" rowspan="1" colspan="1">NAT FP/EIA+</td><td align="right" valign="top" rowspan="1" colspan="1">520 042</td><td align="center" valign="top" rowspan="1" colspan="1">136</td><td align="center" valign="top" rowspan="1" colspan="1">25</td><td align="center" valign="top" rowspan="1" colspan="1">0.0019670</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="right" valign="top" rowspan="1" colspan="1">85 (61&#x02013;109)</td><td align="center" valign="top" rowspan="1" colspan="1">0.26</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;TDF11</td><td align="center" valign="top" rowspan="1" colspan="1">F</td><td align="left" valign="top" rowspan="1" colspan="1">NAT FP/EIA+</td><td align="right" valign="top" rowspan="1" colspan="1">2340</td><td align="center" valign="top" rowspan="1" colspan="1">367</td><td align="center" valign="top" rowspan="1" colspan="1">17</td><td align="center" valign="top" rowspan="1" colspan="1">0.0015150</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="right" valign="top" rowspan="1" colspan="1">47 (25&#x02013;69)</td><td align="center" valign="top" rowspan="1" colspan="1">0.33</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;TDF12</td><td align="center" valign="top" rowspan="1" colspan="1">M</td><td align="left" valign="top" rowspan="1" colspan="1">NAT FP/EIA+</td><td align="right" valign="top" rowspan="1" colspan="1">21 400</td><td align="center" valign="top" rowspan="1" colspan="1">BLQ</td><td align="center" valign="top" rowspan="1" colspan="1">23</td><td align="center" valign="top" rowspan="1" colspan="1">0.0017940</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="right" valign="top" rowspan="1" colspan="1">75 (49&#x02013;100)</td><td align="center" valign="top" rowspan="1" colspan="1">0.48</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;TDF13</td><td align="center" valign="top" rowspan="1" colspan="1">M</td><td align="left" valign="top" rowspan="1" colspan="1">NAT FP/EIA+</td><td align="right" valign="top" rowspan="1" colspan="1">15 612</td><td align="center" valign="top" rowspan="1" colspan="1">BLQ</td><td align="center" valign="top" rowspan="1" colspan="1">22</td><td align="center" valign="top" rowspan="1" colspan="1">0.0008009</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="right" valign="top" rowspan="1" colspan="1">20 (13&#x02013;27)</td><td align="center" valign="top" rowspan="1" colspan="1">0.53</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;TDF14</td><td align="center" valign="top" rowspan="1" colspan="1">M</td><td align="left" valign="top" rowspan="1" colspan="1">NAT FP/EIA+</td><td align="right" valign="top" rowspan="1" colspan="1">20 194</td><td align="center" valign="top" rowspan="1" colspan="1">BLQ</td><td align="center" valign="top" rowspan="1" colspan="1">17</td><td align="center" valign="top" rowspan="1" colspan="1">0.0012650</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="right" valign="top" rowspan="1" colspan="1">49 (29&#x02013;68)</td><td align="center" valign="top" rowspan="1" colspan="1">0.68</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;TDF15</td><td align="center" valign="top" rowspan="1" colspan="1">M</td><td align="left" valign="top" rowspan="1" colspan="1">NAT FP/EIA+</td><td align="right" valign="top" rowspan="1" colspan="1">1276</td><td align="center" valign="top" rowspan="1" colspan="1">19.9</td><td align="center" valign="top" rowspan="1" colspan="1">10</td><td align="center" valign="top" rowspan="1" colspan="1">0.0011110</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="right" valign="top" rowspan="1" colspan="1">42 (24&#x02013;60)</td><td align="center" valign="top" rowspan="1" colspan="1">0.32</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;TDF16</td><td align="center" valign="top" rowspan="1" colspan="1">M</td><td align="left" valign="top" rowspan="1" colspan="1">NAT FP/EIA+</td><td align="right" valign="top" rowspan="1" colspan="1">771</td><td align="center" valign="top" rowspan="1" colspan="1">86</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;TDF17</td><td align="center" valign="top" rowspan="1" colspan="1">F</td><td align="left" valign="top" rowspan="1" colspan="1">NAT FP/EIA+</td><td align="right" valign="top" rowspan="1" colspan="1">315</td><td align="center" valign="top" rowspan="1" colspan="1">56</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td colspan="10" align="left" valign="top" rowspan="1">Placebo group</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;PL1</td><td align="center" valign="top" rowspan="1" colspan="1">F</td><td align="left" valign="top" rowspan="1" colspan="1">NAT FP/EIA+</td><td align="right" valign="top" rowspan="1" colspan="1">3635</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">17</td><td align="center" valign="top" rowspan="1" colspan="1">0.0019850</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="right" valign="top" rowspan="1" colspan="1">84 (58&#x02013;109)</td><td align="center" valign="top" rowspan="1" colspan="1">0.43</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;PL2</td><td align="center" valign="top" rowspan="1" colspan="1">F</td><td align="left" valign="top" rowspan="1" colspan="1">NAT FP/EIA+</td><td align="right" valign="top" rowspan="1" colspan="1">425 225</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">21</td><td align="center" valign="top" rowspan="1" colspan="1">0.0202400</td><td align="center" valign="top" rowspan="1" colspan="1">6</td><td align="right" valign="top" rowspan="1" colspan="1">112 (82&#x02013;142)</td><td align="center" valign="top" rowspan="1" colspan="1">0.02</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;PL3</td><td align="center" valign="top" rowspan="1" colspan="1">F</td><td align="left" valign="top" rowspan="1" colspan="1">NAT FP/EIA+</td><td align="right" valign="top" rowspan="1" colspan="1">15 010</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">18</td><td align="center" valign="top" rowspan="1" colspan="1">0.0152300</td><td align="center" valign="top" rowspan="1" colspan="1">5</td><td align="right" valign="top" rowspan="1" colspan="1">74 (48&#x02013;101)</td><td align="center" valign="top" rowspan="1" colspan="1">0.05</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;PL4</td><td align="center" valign="top" rowspan="1" colspan="1">F</td><td align="left" valign="top" rowspan="1" colspan="1">NAT FP/EIA+</td><td align="right" valign="top" rowspan="1" colspan="1">95 892</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">20</td><td align="center" valign="top" rowspan="1" colspan="1">0.0013210</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="right" valign="top" rowspan="1" colspan="1">46 (34&#x02013;59)</td><td align="center" valign="top" rowspan="1" colspan="1">0.55</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;PL5</td><td align="center" valign="top" rowspan="1" colspan="1">M</td><td align="left" valign="top" rowspan="1" colspan="1">NAT FP/EIA+</td><td align="right" valign="top" rowspan="1" colspan="1">374 746</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">18</td><td align="center" valign="top" rowspan="1" colspan="1">0.0068250</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="right" valign="top" rowspan="1" colspan="1">295 (243&#x02013;348)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;PL6</td><td align="center" valign="top" rowspan="1" colspan="1">M</td><td align="left" valign="top" rowspan="1" colspan="1">NAT FP/EIA+</td><td align="right" valign="top" rowspan="1" colspan="1">294 000</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">20</td><td align="center" valign="top" rowspan="1" colspan="1">0.0011890</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="right" valign="top" rowspan="1" colspan="1">18 (9&#x02013;27)</td><td align="center" valign="top" rowspan="1" colspan="1">0.60</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;PL7</td><td align="center" valign="top" rowspan="1" colspan="1">M</td><td align="left" valign="top" rowspan="1" colspan="1">NAT FP</td><td align="right" valign="top" rowspan="1" colspan="1">1 950 000</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">23</td><td align="center" valign="top" rowspan="1" colspan="1">0.0002609</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="right" valign="top" rowspan="1" colspan="1">12 (4&#x02013;20)</td><td align="center" valign="top" rowspan="1" colspan="1">0.67</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;PL8</td><td align="center" valign="top" rowspan="1" colspan="1">M</td><td align="left" valign="top" rowspan="1" colspan="1">NAT FP/EIA+</td><td align="right" valign="top" rowspan="1" colspan="1">35 752</td><td align="center" valign="top" rowspan="1" colspan="1">BLQ</td><td align="center" valign="top" rowspan="1" colspan="1">16</td><td align="center" valign="top" rowspan="1" colspan="1">0.0568900</td><td align="center" valign="top" rowspan="1" colspan="1">7</td><td align="right" valign="top" rowspan="1" colspan="1">197 (150&#x02013;244)</td><td align="center" valign="top" rowspan="1" colspan="1">0.00</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;PL9</td><td align="center" valign="top" rowspan="1" colspan="1">M</td><td align="left" valign="top" rowspan="1" colspan="1">NAT FP/EIA+</td><td align="right" valign="top" rowspan="1" colspan="1">9730</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">13</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="right" valign="top" rowspan="1" colspan="1">nc</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;PL10</td><td align="center" valign="top" rowspan="1" colspan="1">M</td><td align="left" valign="top" rowspan="1" colspan="1">NAT FP/EIA+</td><td align="right" valign="top" rowspan="1" colspan="1">23 891</td><td align="center" valign="top" rowspan="1" colspan="1">BLQ</td><td align="center" valign="top" rowspan="1" colspan="1">14</td><td align="center" valign="top" rowspan="1" colspan="1">0.0042530</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="right" valign="top" rowspan="1" colspan="1">54 (29&#x02013;80)</td><td align="center" valign="top" rowspan="1" colspan="1">0.82</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;PL11</td><td align="center" valign="top" rowspan="1" colspan="1">M</td><td align="left" valign="top" rowspan="1" colspan="1">NAT FP/EIA+</td><td align="right" valign="top" rowspan="1" colspan="1">324 797</td><td align="center" valign="top" rowspan="1" colspan="1">BLQ</td><td align="center" valign="top" rowspan="1" colspan="1">17</td><td align="center" valign="top" rowspan="1" colspan="1">0.0017060</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="right" valign="top" rowspan="1" colspan="1">65 (48&#x02013;82)</td><td align="center" valign="top" rowspan="1" colspan="1">0.18</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;PL12</td><td align="center" valign="top" rowspan="1" colspan="1">M</td><td align="left" valign="top" rowspan="1" colspan="1">NAT FP/EIA+</td><td align="right" valign="top" rowspan="1" colspan="1">3 030 000</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">16</td><td align="center" valign="top" rowspan="1" colspan="1">0.0002500</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="right" valign="top" rowspan="1" colspan="1">11 (2&#x02013;20)</td><td align="center" valign="top" rowspan="1" colspan="1">0.68</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;PL13</td><td align="center" valign="top" rowspan="1" colspan="1">M</td><td align="left" valign="top" rowspan="1" colspan="1">NAT FP/EIA+</td><td align="right" valign="top" rowspan="1" colspan="1">180 000</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">19</td><td align="center" valign="top" rowspan="1" colspan="1">0.0004211</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="right" valign="top" rowspan="1" colspan="1">5 (&#x02212;2&#x02013;12)</td><td align="center" valign="top" rowspan="1" colspan="1">0.75</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;PL14</td><td align="center" valign="top" rowspan="1" colspan="1">M</td><td align="left" valign="top" rowspan="1" colspan="1">NAT FP/EIA+</td><td align="right" valign="top" rowspan="1" colspan="1">284 920</td><td align="center" valign="top" rowspan="1" colspan="1">BLQ</td><td align="center" valign="top" rowspan="1" colspan="1">18</td><td align="center" valign="top" rowspan="1" colspan="1">0.0004444</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="right" valign="top" rowspan="1" colspan="1">16 (6&#x02013;25)</td><td align="center" valign="top" rowspan="1" colspan="1">0.65</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;PL15</td><td align="center" valign="top" rowspan="1" colspan="1">M</td><td align="left" valign="top" rowspan="1" colspan="1">NAT FP/EIA+</td><td align="right" valign="top" rowspan="1" colspan="1">687 126</td><td align="center" valign="top" rowspan="1" colspan="1">BLQ</td><td align="center" valign="top" rowspan="1" colspan="1">22</td><td align="center" valign="top" rowspan="1" colspan="1">0.0005714</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="right" valign="top" rowspan="1" colspan="1">22 (7&#x02013;37)</td><td align="center" valign="top" rowspan="1" colspan="1">0.13</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;PL16</td><td align="center" valign="top" rowspan="1" colspan="1">M</td><td align="left" valign="top" rowspan="1" colspan="1">NAT FP/EIA+</td><td align="right" valign="top" rowspan="1" colspan="1">563 000</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">17</td><td align="center" valign="top" rowspan="1" colspan="1">0.0098670</td><td align="center" valign="top" rowspan="1" colspan="1">4</td><td align="right" valign="top" rowspan="1" colspan="1">45 (23&#x02013;67)</td><td align="center" valign="top" rowspan="1" colspan="1">0.00</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p id="P42">BLQ, below the limit of quantification; EIA+, enzyme immunoassay positive; NAT FP, nucleic acid testing first positive; nc, not computed; SPMM, Shifted Poisson Mixture Model; TDF, tenofovir disoproxil fumarate.</p></fn><fn id="TFN2"><label>a</label><p id="P43">A small (&#x0003c;0.1 for Poisson-Fitter and &#x0003c;0.05 for SPMM) <italic toggle="yes">P</italic> value denotes divergence from a Poisson distribution and a bad fit to the model.</p></fn><fn id="TFN3"><label>b</label><p id="P44">Reported values for samples TDF4, TDF8, TDF10, PL2, PL3, PL5, PL8, and PL16 were generated by SPMM.</p></fn></table-wrap-foot></table-wrap></floats-group></article>